Trial Profile
Postoperative Adjuvant Radiochemotherapy (aRCH) With Cisplatin (C) Versus aRCH With C and Pembrolizumab (P) in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); Multicenter Randomized Phase II Study Within the German Interdisciplinary Study Group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ADRISK
- 05 Sep 2023 Planned End Date changed from 1 Aug 2024 to 1 Jan 2025.
- 05 Sep 2023 Planned primary completion date changed from 1 Aug 2024 to 1 Jan 2025.
- 13 Sep 2022 Trial design, presented at the 47th European Society for Medical Oncology Congress